BNTX:NASDAQ
BioNTech SE
US$Â 97.64
arrow_upward
+0.76%(+0.74) Siku 1
US$Â 97.64
0.00% (0.00)
bedtimeBaada ya saa
Imefungwa: 5 Okt, 16:00:01 GMT -4 · USD
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya BNTX...
Fungua
US$Â 96.74
Juu
US$Â 98.78
Chini
US$Â 95.20
Mtaji wa soko
24.53B
Wastani wa kiasi cha mauzo
1.10M
Kiasi cha mauzo ya hisa
1.44M
Juu kwa wiki 52
US$Â 123.98
Chini kwa wiki 52
US$Â 79.52
EPS
-US$Â 7.55
Beta
1.22
Hisa za wawekezaji
251.20M
Idadi ya wafanyakazi
elfu 8
Fungua
US$Â 96.74
Juu
US$Â 98.78
Chini
US$Â 95.20
Mtaji wa soko
24.53B
Wastani wa kiasi cha mauzo
1.10M
Kiasi cha mauzo ya hisa
1.44M
Juu kwa wiki 52
US$Â 123.98
Chini kwa wiki 52
US$Â 79.52
EPS
-US$Â 7.55
Beta
1.22
Hisa za wawekezaji
251.20M
Idadi ya wafanyakazi
elfu 8
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
Yahoo Finance
·
saa 1 iliyopita
Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips
AD HOC NEWS
·
saa 4 zilizopita
BioNTech stock draws Moderate Buy consensus at USD 126 target
AD HOC NEWS
·
saa 9 zilizopita
BioNTech CEO Offloads 100,000 Shares as Founders' Exit Talks Turn Testy
AD HOC NEWS
·
saa 13 zilizopita
Berenberg raises target for BioNTech stock from USD 132 to USD 140
Wasifu
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
Kuhusu BioNTech SE